Zacks Small Cap Research on MSN

FBLG: Phase 1/2 trial of CYWC628 underway

By David Bautz, PhD NASDAQ: FBLG Business Update Phase 1/2 Trial of CYWC628 Underway On June 3, 2026, FibroBiologics, Inc.

Exclusive: FibroBiologics doses first patients in diabetic foot ulcers clinical trial

FibroBiologics Inc. FBLG on Wednesday announced that it has enrolled and dosed the first patients in its Phase 1/2 clinical ...
Nasdaq

FibroBiologics Presents Research on Human Dermal Fibroblast Spheroids for Psoriasis Therapy at SID Annual Meeting

FibroBiologics, Inc., a biotechnology company focused on developing therapies for chronic diseases using fibroblasts, announced that Dr. Chuo Fang presented research at the Society for Investigative ...
Yahoo Finance

Fibroblast Activation Protein (FAP) Targeted Therapy Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Therapies by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Fibroblast Activation Protein (FAP) Targeted Therapy: a Competitor Analysis" report has been added to ResearchAndMarkets.com's offering. This competitive ...

FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers

Detailed price information for Fibrobiologics Inc (FBLG-Q) from The Globe and Mail including charting and trades.
Nasdaq

FibroBiologics, Inc. Announces Investor Webinar on Innovative Fibroblast-Based Cell Therapy Platform

FibroBiologics, Inc., a clinical-stage biotechnology company focused on developing therapies for chronic diseases through fibroblasts, announced an investor webinar scheduled for July 10, 2025, at ...

Is FibroBiologics, Inc. (FBLG) Advancing Toward a Breakthrough Psoriasis Treatment With CYPS317 Data?

We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. FibroBiologics, Inc. (NASDAQ:FBLG) ...